Investment

All the way from regenerative research to commercialisation

We speak to the director of the Wake Forest Institute of Regenerative Medicine – a research organisation with a clear focus on commercialisation. Just on...

$85m funding for epigenetic platform technology

Omega Therapeutics secures $85m to carry out clinical trials into epigenetic treatments for five key disease areas – and potentially for Covid-19.  While you might...

Tonus seeks early-stage funding for exoskeleton tech

Company spawned by London start-up generator targets middle-aged recreational athletes with exoskeleton leggings powered by soft robotics. Back in November, we brought you the story...

Aubrey de Grey: “Damage repair is the future of Longevity medicine”

SENS Research Foundation's Aubrey de Grey on increasing investor appetites and the elephant in the Longevity room. Continuing our series of interviews with our Advisory Panel...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

de Magalhães interview: “Still lots of work to do”

Professor João Pedro de Magalhães on different areas of Longevity. Continuing our series of interviews with our Advisory Panel members, we caught up with João Pedro...

SyndicateRoom co-founder joins First Longevity

Tom Britton joins Advisory Panel as plans for Longevity equity funding platform take another step forward. Longevity.Technology: Just last month we announced the formation of...

Hufford interview: “It’s worth pointing out just how remarkable this is.”

LyGenesis' Michael Hufford talks Longevity research programmes and investment. Kicking off a series of interviews with our Advisory Panel members, we chatted to Michael Hufford,...

Longevity investment: Apollo aims for the moon

Co-founder of Longevity-focused investment firm shows you can target aging AND appeal to biotech investors. Founded in 2016, Berlin and Boston-based Apollo already boasts an...

Cosmetic therapeutic senolytics: aging isn’t just skin-deep

When is a cosmetic product also a therapy? When it's a patented senolytic that tackles aging at a cellular level. OneSkin began life validating how...

Leading academic “profoundly disappointed” by COVID-19 response

Professor Richard Faragher asks why developments in aging research have been largely ignored in the global response to the COVID-19 pandemic. With the world currently...

Deep Longevity exits stealth to partner with HLI

Insilico announces Deep Longevity, a spin-out that will collaborate with Human Longevity Inc. to deploy an extensive range of AI-powered aging clocks. Insilico Medicine has...

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details. The global Longevity...

Sun Genomics raises $8.5m to drive market share

Personalised gut health testing market is hotting-up and could revolutionise anti-aging intervention tracking. San Diego-headquartered microbiome health company Sun Genomics is set to build on...

Top 5 categories for Longevity investors

Our current survey is throwing-up some great data. Here's a taster of what we've learned from Longevity investors. We're currently running our surveys for Longevity...

3 minutes of your time to help us help you

Calling all Longevity investors, founders, c-suite and university spin-outs. Longevity is hotting-up and we're asking for 3 minutes of your time to help us help...

First Longevity: announcing our premier league Advisory Panel

More news from us, as we announce our new Advisory Panel. Last week we announced the appointment of George Sutherland as the Chairman of First...

David Sinclair seeks £100m for anti-aging fight

Life Biosciences' new fundraising push seeks answers to big aging questions, but won't be drawn on its strategy. Harvard scientist David Sinclair is one of...

First Longevity appoints George Sutherland as Chairman

Some news of our own: we're expanding our Board and funding for growth. Health and med-tech leader, George Sutherland, enters the Longevity industry to support...

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...